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Clinical Efficacy of Diphenylcyclopropenone in
Alopecia Areata: Retrospective Data Analysis
of 50 Patients
Katherine S. Chiang1,2, Natasha A. Mesinkovska1, Melissa P. Piliang1 and Wilma F. Bergfeld1
Diphenylcyclopropenone (DPCP) is widely considered the most effective topical immunotherapy for refractory or
extensive alopecia areata (AA), but questions regarding how long to try DPCP therapy before terminating and
what factors are prognostic of therapeutic success still remain unanswered. In this retrospective study of 50 AA
patients, we evaluated DPCP efficacy and identified patient factors predictive of therapeutic success/failure. The
median duration of DPCP treatment was 3 years, with 47% patients experiencing their first regrowth in the
first 6 months of DPCP therapy, 20% between 6 months–1 year, and 8% between 1–2 years. In our study, treatment
success, defined as X50% terminal hair regrowth, was reached in 71% of alopecia totalis patients and in
56% of alopecia universalis patients. Three factors were statistically significant predictors of poor treatment
outcome—extent of hair loss before DPCP treatment, history of thyroid disease, and extent of body hair
involvement. Relapse was observed in 44% of patients and significantly associated with history of thyroid disease.
Common side effects were itching, rash, and local lymphadenopathy. The results of this study support our belief
that DPCP therapy is a viable treatment option, can be successfully accomplished at home, and should not be
terminated before 2 years.
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INTRODUCTION
Alopecia areata (AA) is a non-scarring type of hair loss that
affects both genders and all ethnicities. Calculated lifetime risk
is B2% of the population (Alkhalifah, 2013). The
characteristic lesions are well-defined smooth round bald
patches on the scalp or any other hair-bearing area of the
body. This patchy pattern of hair loss may present at any age,
but up to 66% of patients present before 30 years of age
(Gilhar et al., 2012). In some patients, AA can progress to
alopecia totalis (total loss of scalp hair) or to alopecia
universalis (total loss of all scalp and body hair).
The exact pathophysiology of AA remains poorly under-
stood. Current evidence suggests that AA is an autoimmune
disease with a genetic predisposition and an environmental
trigger. A family history has been noted in 10–42% of cases,
and triggers like emotional stress and trauma have also been
correlated (de Andrade et al., 1999). AA is associated with
more than 20 HLA class I and class II alleles, as well as an
increased overall risk for other autoimmune disorders like
diabetes mellitus type 1, systemic lupus erythematous, and
autoimmune thyroid disease (Alzolibani, 2011).
AA most commonly presents as minor patchy hair loss and
usually resolves spontaneously. In B7% of cases, alopecia
area will evolve into a severe and chronic hair loss (Safavi
et al., 1995). Studies have shown that AA can cause
devastating emotional distress in patients. Therefore,
treatments, though optional, offer psychological support to
foster increased self-esteem (Tucker, 2009). No cure or
preventive treatment for AA has been established, and
current treatments are directed towards halting disease
activity. Corticosteroid (topical, local injections, and
systemic) are the most popular and efficacious treatments for
AA, but long-term application often leads to skin atrophy.
Therefore therapies like topical immunotherapy,
phototherapy, minoxidil, and anthralin are also being used.
Topical immunotherapy is the best documented treatment for
severe or refractory AA (Singh et al., 2007).
Three topical sensitizers have been used in topical immu-
notherapy treatment for AA. Dinitrochlorobenzene was first to
be used, but has been discontinued because of its possible
mutagenicity. Squaric acid dibutylester and diphenylcyclopro-
penone (DPCP) are the two compounds still in use today.
DPCP is considered as the most effective topical immunother-
apy for AA treatment and is currently the preferred topical
sensitizer owing to its low cost, stability in solution, and non-
mutagenic properties. It has been in use since 1983. The exact
ORIGINAL ARTICLE
1Department of Dermatology, Cleveland Clinic Foundation, Cleveland, Ohio, USA and 2Case Western Reserve University School of Medicine, Cleveland, Ohio,
USA
Correspondence: Wilma F. Bergfeld, Department of Dermatology, Cleveland Clinic Foundation, 9500 Euclid Avenue, A61, Cleveland, Ohio 44195, USA. E-mail:
bergfew@ccf.org
Abbreviations: AA, alopecia areata; DPCP, Diphenylcyclopropenone
50 The Journal of Investigative Dermatology Symposium (2015), Volume 17 & 2015 The Society for Investigative Dermatology
mechanism of action of DPCP is poorly understood, but it may
include antigenic competition and decreased production of
anti-hair-follicle antibodies (Tobin et al., 2002). Regrowth
rates observed with DPCP range from 33 to 83%, averaging
at 50% (Cotellessa et al., 2001; Aghaei, 2005; Avgerinou
et al., 2008). The repetitive application of DPCP induces an
allergic contact dermatitis. Side effects of DPCP include
persistent dermatitis, blistering, spread of contact eczema,
lymph node enlargement, pigment changes, and secondary
infection.
In this study we aimed to evaluate the clinical efficacy,
tolerability, and prognostic factors of DPCP therapy to identify
patient and treatment factors predictive of therapeutic success.
RESULTS
The demographic and clinical data are depicted in Table 1.
The study included 50 subjects with AA. All patients had
undergone prior treatments for AA including intralesional
steroids (82% of patients), topical steroids (64%), topical
minoxidil (46%), and oral steroids (44%). After sensitization
with 2% DPCP solution, 1 of the 50 patients failed to develop
erythema or mild eczematous response to DPCP and was
classified as anergic. This patient was excluded and 49
patients were available for the final analysis.
None of the patients discontinued DPCP therapy because of
adverse effects, but side effects were reported by 23 patients
(47%). Ten patients (20%) experienced lymph node swelling,
11 experienced blistering (22%), 11 experienced spreading of
contact eczema (22%), and 11 experienced severe itching
(22%). Of the patients who experienced side effects, the
majority experienced at least two. Two patients (4%) experi-
enced all four side effects.
In our study, the duration of DPCP treatment ranged from 6
months to 15 years, with a median of 3 years. The first clinical
evidence of hair regrowth was detected at a median duration
of 5 months after the onset of DPCP therapy (range: 1–46
months). Those who experienced more than 50% regrowth
saw regrowth after an average of 7 months whereas those who
had minimal response experienced their first regrowth after an
average of 14 months. Statistical analysis did not establish
significant association between the time to first regrowth and
treatment outcome (P¼ 0.063).
The initial concentration of DPCP used post-sensitization
ranged from 0.0001 to 1% with a median of 0.001%. The first
detectable eczematous scalp reaction was elicited at a median
concentration of 0.01% (range 0.0001–1%). The first detect-
able terminal hair regrowth was elicited at a median concen-
tration of 0.001% (range 0.000001–0.0.1%). The highest
concentration of DPCP used ranged from 0.001 to 7% with
a median of 0.1%.
Treatment success (X50% terminal hair regrowth) was
reached in 66% of cases. Nineteen patients (39%) achieved
complete regrowth (490% terminal hair), 13 patients (27%)
had partial regrowth (50–90% terminal hair), 7 patients (14%)
had minimal regrowth (o50% terminal hair), and 11 patients
(22%) had no regrowth (0–10% terminal hair). Statistical
analysis established a significant association between the
extent of hair loss before DPCP treatment and treatment
outcome (P¼0.020, odds ratio¼ 3.34). This suggests that
the odds of achieving at least 50% terminal hair regrowth
was 3 times more likely in those with severe loss (50–74%)
than in those with total loss (75–100%) and about 3 times
more likely in those with moderate loss (25–49%) than in
those with severe loss (50–74%). In this study,X50% terminal
hair regrowth was achieved in 52% of those with total hair
Table 1. Demographic and clinical data1
Demographic data
Number of patients 50
Anergic patients (not assessed in the further analysis) 1
Gender (M/F) 14 (28)/36 (72)
Race
Caucasian 46 (92)
Black 3 (6)
Asian 1 (2)
Age at disease onset (years)
Median 21
Range 3–59
Age of beginning of therapy (years)
Median 37.5
Range 10–61
Disease duration before treatment (years)
Median 5
Range 2 months–45 years
Clinical data
Type of alopecia areata
Patchy 9 (18)
Totalis 14 (29)
Universalis 25 (51)
Ophiasis 1 (2)
Extent of scalp hair loss
Total (75–100%) 25 (51)
Severe (50–74%) 15 (31)
Moderate (25–49%) 8 (16)
Mild (0–24%) 1 (2)
Comorbidities
Thyroid dysfunction 25 (51)
Atopy 27 (55)
Anemia 14 (29)
PCOS 3 (6)
Nail changes 10 (20)
Body hair involvement 35 (71)
Positive family history
Alopecia areata 11 (22)
Autoimmune disease 31 (63)
Abbreviation: PCOS, polycystic ovary syndrome.
1Values in parentheses are expressed as percentages.
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loss, 66% of those with severe hair loss, and in 100% of those
with moderate or mild hair loss (Figure 1).
Statistical analysis did not establish a significant association
between alopecia subtype and treatment outcome (P¼0.152).
However, we observed that the more severe the alopecia
subtype, the smaller the proportion of patients that achieved
treatment success. Eight patients with patchy alopecia (89%)
and 10 patients with alopecia totalis (71%) saw regrowth of
450%. By contrast, only 14 patients with alopecia universalis
(56%), and 0 patients with the ophiasis-type alopecia achieved
at least 50% terminal hair regrowth (Figure 2).
Parameters such as atopy, family history of AA, nail
involvement, age at disease onset, and interval between
disease onset and DPCP therapy failed to modify DPCP
response in our analysis (Table 2). Two factors—history of
thyroid disease (P¼0.046) and extent of body hair involve-
ment (P¼ 0.034)—however, appeared to be prognostic of
treatment outcome. In our study, patients with a history of
thyroid disease were less likely to achieve therapeutic success
compared with those who did not have any history of thyroid
disease. Furthermore, logistic regression revealed that the
greater the extent of body hair involvement the smaller the
probability of therapeutic success.
Long-term follow-up of DPCP therapy showed that 17 of the
39 patients who initially responded to treatment relapsed
within 4 years (44%). The median time to relapse after DPCP
onset was 20 months (range: 5–54 months). The risk of relapse
was not significantly related to the baseline extent of hair loss
at the initiation of therapy (P¼0.97). Other continuous factors
including age of disease onset, age at DPCP onset, duration
between disease and DPCP onset, and extent of body hair
involvement were not predictive of relapse. Categorical factors
such as atopy, anemia, family history of AA, and nail
involvement did not modify relapse in our analysis
(Table 3). The only factor that was significantly associated
with relapse was history of thyroid disease. In our analysis,
62% of the patients with a history of thyroid disease experi-
enced relapse compared with only 22% of patients with no
history of thyroid disease (P¼ 0.013).
DISCUSSION
In our study, a total response rate of 78% was achieved: 38%
with complete response, 26% with partial response, and 14%
with minimal response. Previous studies have reported
response rates of DPCP between 33 and 83% (Table 4); the
present study (78%) is on the higher side of this range (van der
Steen et al., 1991; Gordon et al., 1996; Sharma and
Muralidhar, 1998; Cotellessa et al., 2001; Wiseman et al.,
2001; Aghaei, 2005; Sotiriadis et al., 2007; Avgerinou et al.,
2008). Two other studies found similar response rates at 77.9
and 81.5% (Wiseman et al., 2001; Aghaei, 2005).
These differences in response rates may be attributed to
variations in study methodologies such as inclusion/exclusion
criterion, and in the ambiguous definition of ‘‘clinical
response’’. Previous studies have defined response to be
cosmetically acceptable hair regrowth, total hair regrowth,
or a specific percentage of hair regrowth. In this study, total
response rate was defined as the percentage of patients with
410% terminal hair regrowth. Other factors that may have
contributed to the higher response rate in our study include
treatment duration, and immunotherapy protocol. The median
treatment duration for our study was 3 years, which is to our
knowledge, longer than that of any previous study on DPCP
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Figure 1. Treatment outcome for various extents of hair loss.
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Figure 2. Treatment outcome for each alopecia subtype.
Table 2. Prognostic factors for treatment response
Factors P-value Odds ratio (95% CI)
Categorical factors
Thyroid disease 0.046 3.5 (0.996–12.359)
Atopy 0.835 0.875 (0.269–2.850)
Family history of AA 0.895 1.099 (0.271–4.454)
Nail Involvement 0.693 1.33 (0.319–5.570)
Continuous factors
Age of disease onset 0.817 0.995 (0.956–1.036)
Age at DPCP onset 0.802 1.005 (0.966–1.046)
Duration between disease
and DPCP onset
0.593 1.014 (0.964–1.067)
Extent of hair loss 0.020 3.341 (1.213–9.197)
Extent of body hair involvement 0.034 2.283 (1.062–4.906)
Abbreviations: AA, alopecia areata; CI, confidence interval;
DPCP, diphenylcyclopropenone.
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treatment for AA (range: 6 months to 30 months). Immu-
notherapy protocol for our study was also distinctly different
from that of other studies because patients applied the DPCP
solution twice-weekly at home instead of coming into the
office for weekly nurse-administered treatment as is the
common practice.
Our treatment success rate for the alopecia totalis (71%)
and alopecia universalis (56%) patients are higher than that of
previous studies which have reported response rates of 17.4,
20.8, and 31% (Wiseman et al., 2001; Sotiriadis et al., 2007;
Ohlmeier et al., 2012). We attribute this difference primarily
to the longer duration of treatment and titration of DPCP to
maintain controlled mild contact sensitivity.
Many prognostic factors for DPCP treatment outcome have
been described in the literature. They include type of AA,
extent of alopecia, age at disease onset, age at DPCP onset,
duration of AA before initiation of DPCP therapy, family
history of AA, presence of atopic dermatitis, and presence of
nail changes (Rokhsar et al., 1998; Wasserman et al., 2007). In
this study, we found extent of hair loss before DPCP treatment
to be the single most prognostic factor for clinical outcome.
This was unsurprising, as this association has been
documented in three previous studies (van der Steen et al.,
1991; Wiseman et al., 2001; Ohlmeier et al., 2012). What was
surprising was the discovery that two additional factors—
history of thyroid disease and extent of body hair
involvement—were prognostic for poorer therapeutic out-
come. These factors are perhaps indicators of a more systemic
and widespread immune response. The lack of previous
studies to support or oppose this finding points to an
opportunity in future research on DPCP therapy. History of
thyroid disease, especially, is a factor of particular interest
because it is a negative prognostic factor of both therapeutic
success and relapse in this study.
Table 3. Prognostic factors for relapse
Factors P-value Odds ratio (95% CI)
Categorical factors
Thyroid disease 0.013 0.176 (0.43–0.73)
Atopy 0.065 3.467 (0.90–13.31)
Anemia 0.110 3.022 (0.76–11.99)
Family history of AA 0.226 2.639 (0.53–13.12)
Nail involvement 0.101 4.167 (0.70–24.94)
Continuous factors
Age of disease onset 0.806 1.005 (0.966–1.046)
Age at DPCP onset 0.858 1.004 (0.962–1.048)
Duration between disease
and DPCP onset
0.595 0.984 (0.925–1.045)
Extent of hair loss 0.977 1.011 (0.485–2.109)
Extent of body hair involvement 0.818 0.926 (0.483–1.777)
Abbreviations: AA, alopecia areata; CI, confidence interval; DPCP, diphe-
nylcyclopropenone.
Table 4. Results of previously reported studies on DPCP treatment in AA patients
Author
Number of
people Response rate percentage
Duration of DPCP
therapy Relapse percentage
Follow-up
time
Ohlmeier et al., 2012 142 53% had 450% regrowth
72% had 410% regrowth
64.9% had 450% regrowth in patchy AA
20.8% had 450% regrowth in AU/AT
Mean of 20 months 45.1% total
(70.4% in those who discontinued
DPCP
and 16.7% in those who continued
with DPCP)
36 months
Sotiriadis et al., 2007 41 39.5% had significant hair regrowth
43.4% had 480% regrowth in patchy AA
33.3% had 480% regrowth in AU/AT
12 months 33.4% (discontinued DPCP) 12 months
Aghaei, 2005 28 81.5% showed aggregate response 6 months 50.9% (continuedþ discontinued
with DPCP)
6–12 months
Wiseman et al., 2001 148 77.9% had cosmetically acceptable
or 475% regrowth
17.4% had cosmetically acceptable or 475%
regrowth in AU/AT
32 months 62.6% 37 months
Avgerinou et al.,
2008
64 83.3%
33.3% showed response in AU/AT
24 months 68.9% (discontinued DPCP) 24 months
Cotellessa et al., 2001 56 48% showed aggregate response 6 months 40% (discontinued DPCP) Mean 12
months
Sharma and
Muralidhar, 1998
15 33% showed aggregate response 12 months
Gordon et al., 1996 48 38% showed aggregate response Mean of 30.8
months
28.1% (continued DPCP) Mean 19.8
months
van der Steen et al.,
1991
139 50.4% showed aggregate response Not reported Not reported Not reported
Abbreviations: AA, alopecia areata; AT, alopecia totalis; AU, alopecia universalis; DPCP, diphenylcyclopropenone.
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In this study, our relapse rate of 44% falls within the range
reported by previous studies (34 to 68.9%). One study found a
similar relapse rate at 45.1% (Ohlmeier et al., 2012). We
believe that the differences in relapse rate may be owing to
variations in the follow-up period, which range from 6 months
to 37 months. Studies with a shorter observation period tend to
report a lower relapse rate. The notion of a follow-up period
does not apply to our study because patients were not tapered-
off DPCP therapy once complete hair regrowth was achieved.
Our low relapse rate may be a result of this practice, but may
also be because of the lower proportion of our patients with a
family history of AA, a factor that has been found to be
associated with more frequent relapses. A total of 22% of our
patients had a family history of AA compared with 28 and
37% in studies with higher relapse rates (Wiseman et al.,
2001; Aghaei, 2005). However, as demonstrated by w2
analysis, family history of AA did not have any influence on
the relapse rate of our study.
The practical implications of the study are threefold. First,
we believe that DPCP immunotherapy should not be termi-
nated before 2 years. In our study, 47% patients experienced
their first regrowth in the first 6 months of DPCP therapy, 20%
experience their first regrowth between 6 months and 1 year,
and 8% experienced their first regrowth between 1–2 years. In
addition, two patients experienced their first regrowth after 36
and 46 months each. Had DPCP therapy been terminated at 1
year, 15% of our responders would not have been identified.
Secondly, we advocate for continuation of DPCP application
after complete regrowth has been achieved to increase the
treatment durability. Lastly, we believe that DPCP application
can be successfully accomplished at home.
MATERIALS AND METHODS
A retrospective study was conducted using an institutional review
board-approved database of 50 patients who were diagnosed with AA
and underwent DPCP therapy at the Department of Dermatology at
the Cleveland Clinic Foundation from 1997 to 2012. The diagnosis of
AA was based on clinical and/or histological features, and patients
were categorized into one of four subtypes: patchy alopecia, alopecia
totalis, alopecia univeralis, or alopecia ophiasis. Prior to DPCP
immunotherapy, patients were also subcategorized by the extent of
scalp hair loss: total loss (75–100%), severe loss (50–74%), moderate
loss (25–49%), and mild loss (0–24%).
A total of 36 women and 14 men met the criteria for inclusion in the
study (i.e., chronic AA that had been treated with DPCP for at least 6
months). We evaluated gender, race, alopecia subtype, age at disease
onset, extent of body hair involvement, and extent of nail involve-
ment. We also evaluated past medical history and family history for
AA, anemia, atopy, autoimmune thyroid disease, celiac disease,
vitiligo, diabetes mellitus, rheumatoid arthritis, polycystic ovarian
syndrome, inflammatory bowel disease, and Sjogren’s syndrome.
DPCP therapy followed a standard protocol. It began at the office
with sensitization of a quarter-size area on the occipital scalp with 2%
DPCP solution. Two weeks after the initial sensitizing dose, the
previously sensitized area was challenged with 0.001% DPCP solution
and monitored for signs of overreaction. If blistering or enlarged lymph
nodes were present, the DPCP concentration was reduced to 0.0001%.
Alternatively, if the 0.001% DPCP solution was well tolerated, the
patient began at home, twice-weekly, full-scalp application. The
concentration of the DPCP solution was slowly increased (0.001%,
0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07% and so on) until
erythema or a mild eczematous reaction was reached. In the anergic
patient, an attempt was made to override the patient’s anergy with
increased concentration of DPCP and/or more frequent use. Patients
were educated on the proper application techniques by a nurse
educator. Patients were also advised to leave the treated area unwashed
for at least 2–3 hours after application, and to protect the treated area
from sun exposure with an opaque scarf or hat when the product was
on the skin. All patients gave their informed consent to the therapy.
Once complete or cosmetically acceptable regrowth of scalp hair
was achieved, the frequency of DPCP application was tapered from
twice a week, to once a week, to once every two weeks. DPCP therapy
was not discontinued. In the event of hair loss recurrence, the patient
resumed twice-weekly DPCP application. If no hair growth could be
induced after 2 years, DPCP application was temporarily stopped for 6
months and then resumed if the patient was willing to continue.
To characterize the nature of the DPCP treatment, we identified the
DPCP concentration at four time points, including the initial con-
centration post-sensitization, the concentration at first response
(clinically defined as mild erythema and pruritus with DPCP applica-
tion), the concentration at first terminal hair regrowth, and the highest
applied concentration. We also evaluated the age at DPCP treatment
onset, the duration of the DPCP treatment, and the interval between
the onset of the disease and the start of the DPCP treatment. The
duration between the onset of DPCP treatment and first terminal hair
regrowth was also recorded. All patients in this study had undergone
other treatments for AA before initiating DPCP. These prior medica-
tions were noted, along with treatments that they used concurrently
with DPCP. Side effects that the patient experienced as a result of
DPCP treatment were noted. These included lymph node enlarge-
ment, blistering, spread of contact eczema, headache, severe itching,
and hyperpigmentation.
Treatment success was analyzed according to the percent of hair
regrowth on the scalp and categorized into four groups: complete
response (490% regrowth of terminal hair), partial response (50–90%
regrowth of terminal hair), minimal response (o50% regrowth of
terminal hair), and no response (0–10% regrowth terminal hair). Of
particular interest was the relapse rate, defined as loss of cosmetically
acceptable regrowth of scalp hair.
Statistical assessment of patient data was conducted with the SPSS
Statistics 20.0 software (SPSS, Armonk, NY). Continuous variables
were analyzed with binary logistic regression. Categorical variables
were assessed using the w2 test. Statistical significance was set as a
Po0.05.
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